Home » ABSTRACTS

ABSTRACTS

ABSTRACT

Abstracts anni 2000-2001-2002-2003-2004-2005-2006-2007-2008-2009-2010


 Di Costanzo F., Sdrobolini A., Carlini P., Massidda B., Mattioli R., Iop A., Barletta E., Moscetti L., Recchia F., Tralongo P.:

Randomized trial of gemcitabine (GEM) alone or with 5-fluorouracil continuous infusion (5-FU CI) in the treatment of advanced pancreatic cancer (APC): a phase II multicenter study of the GOIRC.

Abs n° 278O, Annals of Oncology 11 suppl. 4, 2000 
 

Gasperoni S., Di Costanzo F., Sdrobolini A., Manzione L., Cognetti F., on behalf of GOIRC and GOAL:

Capecitabine (C) in combination with paclitaxel (P) in advanced breast cancer (ABC). A dose finding study.

Abs n° E34, Annals of Oncology 11 suppl. 2, 2000 

 

Sdrobolini A., Di Costanzo F., Carlini P., Massidda B., Mattioli R., Iop A., Barletta E., Moscetti L., Recchia F., Ttralongo P.:

Randomized trial of Gemcitabine (GEM) alone or with 5-Fluorouracil continuous infusion (5-FU CI) in the treatment of advanced pancreatic cancer (APC): a phase II multicenter study of the GOIRC.

Abs n° E34, Annals of Oncology 11 suppl. 2, 2000 


 

G. Cocconi, P. Carlini, A. Gamboni, S. Gasperoni, C. Rodinò, S. Zironi, G. Bisagni, S. Porrozzi, F. Cognetti, F. Di Costanzo, R. Canaletti, E. M. Ruggeri, R. Camisa, F. Pucci; Italian Oncology Group for Clinical Research (GOIRC), Parma , Italy:

PELF is more active than FAMTX in metastatic gastric cancer (MGC).

Abs n° 501, Proceedings of ASCO 37th Annual Meeting, vol. 20, 2001 

 

F. Di Costanzo, A. Sdrobolini, P. Carlini, B. Massidda, R. Mattioli, A. Iop, E. Barletta, L. Moscetti, F. Recchia, P. Tralongo:

Gemcitabine (GEM) alone or in combination with 5-Fluorouracil continous infusion (CI) in the treatment of advanced pancreatic cancer (APC): a GOIRC randomized phase II trial.

Abs n° 612, Proceedings of ASCO 37th Annual Meeting, vol. 20, 2001 

 

R. Passalacqua, C. Caminiti, R. Cengarle, D. Potenzoni, C. Porta, R. Camisa, L. Pavone, L. Bidin, A. Frassoldati, A. Contu, C. Buzio; Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy:

Efficacy of a regimen of chronic low dose of Interleukin-2 (IL-2) and a-Interferon (IFN-a) in metastatic renal cell carcinoma (MRCC).

Abs n° 777, Proceedings of ASCO 37th Annual Meeting, vol. 20, 2001 


 

B. Di Blasio, M. Dalla Chiesa, V. Franciosi, M. Michiara, F. Di Costanzo, C. Boni, P. Carlini, L. Acito, S. Gori, L. Cortesi, M. Brugia, R. Camisa, S. Cascinu and G. Cocconi. Institutions of Parma, Perugia, Roma, Terni, Piacenza, Reggio Emilia, Lucca, Thiene, Fermo of the GOIRC Group.

Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon a-2a as first line endocrine treatments in advanced breast cancer: results of a phase III prospective randomised multicentric trials.

Abs A56, Annals of Oncology 13, suppl. 3, 2002 

 

F. Di Costanzo, S. Gasperoni, L. Manzione, M. Tonato, G. Bisagni, S. Bravi, E. Cortesi, P. Carlini, I. Floriani, R. Labianca, for GOIRC & GISCAD.

Postoperative chemotherapy (CT) in resected gastric cancer (GC): follow-up (FUP) vs PELF. Results of an Italian Intergroup (GOIRC & GISCAD) study.

Abs n° 1189, Proceedings of ASCO 39th Annual Meeting, vol. 22, 2003. 

 

F. Di Costanzo, S. Gasperoni, L. Manzione, M. Tonato, G. Bisagni, S. Bravi, E. Cortesi, P. Carlini, I. Floriani, R. Labianca.

Postoperative chemotherapy (CT) in resected gastric cancer (GC): follow-up (FUP) vs PELF. Results of an Italian Intergroup (GOIRC & GISCAD) study.

Abs n° 1*, Annals of Oncology 14 suppl. 4, 2003 


 

S. Gasperoni, C. Boni, E. Cortesi, P. Carlini, G. Luppi, B. Massidda, R. Rossetti, L. Cavanna, R. Carroccio, V. Catalano, F. Mazzoni, L. Messerini, N. Locopo, F. Di Costanzo, GOIRC Italy.

Prognostic factors related to the risk of relapse in radical resected cancer.

Abs n° D61*, Annals of Oncology 14 suppl. 4, 2003 

 

F. Perrone, M. Marangolo, F. Di Costanzo, G. Colucci, L. Repetto, M. Merlano, S. De Placido, V. Torri, G. Comella, R. Labianca, V. Parisi, C. Gallo.

Determinants of costs of insurance policies in clinical trials with non-profit prometers.

Abs n° G18, Annals of Oncology 14 suppl. 4, 2003
 
 

R. Passalacqua, C. Buzio, C. Porta, R. Labianca, A. Frassoldati, S. Buti, D. Pezzuolo, A. Vaglio, G. L. Tomasello, M. Dalla Chiesa, R. Camisa, C. Caminiti.

Phase III, randomised, multicentre, controlled trial of mantenance biotherapy for metastatic renal cell carcinoma with Interleukin-2 and Interferon-alpha-2A. A study of the Italian Oncology Group for Clinical Research (GOIRC).

Abs n° L33, Annals of Oncology 15 suppl. 2, 2004 

 

B. Di Blasio, A. Ardizzoni, R. Camisa, G. Ceci, G. Bisagni, C. Boni, P. Bruzzi, G. Cocconi.

Primary chemotherapy (PC) in operable breast carcinoma comparing CMF with an anthracycline-containing regimen (CMFEV): relationship between the short-term clinical complete response and the long-term outcome.

Abs n° A75, Annals of Oncology 15 suppl. 2, 2004 


 

R. Passalacqua, C. Buzio, R. Labianca, C. Porta, M. Dalla Chiesa, S. Buti, G. Tomasello, R. Camisa, A. Frassoldati, C. Caminiti.

Mantainance biotherapy for metastatic renal cancer with IL-2 and IFN-a: a phase III, randomized, multicentre trial.

Abs n° 417O, Annals of Oncology 15 suppl. 3, 2004


S. Gasperoni, L. Manzione, M. Tonato, G. Bisagni, S. Bravi, E. Cortesi, P. Carlini, I. Floriani, R. Labianca, F. Di Costanzo.

Adjuvant chemotherapy in resected gastric cancer (RGC): results and prognostic factors related to the risk of relapse. Phase III trial fo GOIRC.

Abs n° 879PD, Annals of Oncology 15 suppl. 3, 2004

 

R. Passalacqua, C. Buzio, M. Dalla Chiesa, R. Camisa, C. Porta, R. Labianca, A. Frassoldati, S. Buti, D. Pezzuolo, G. Tomasello, C. Caminiti.

Phase III, randomized, multicentr trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC).

Abs 4605, Proceedings of ASCO 41st Annual Meeting, vol. 23, 2005 


 

R. Mattioli, P. Lippe, L. Giustini, R. Bisonni, L. Acito, A. Contu, C. Boni, A. Frassoldati, T. Tamburrano, L. Imperatori.

The role of pre-medication in elderly patients treated with pegilated liposomial doxorubicin as first-line chemotherapy for metastatic breast cancer: a multicentre phase II study.

Abs 174P, Annals of Oncology 17 suppl. 9, 2006 

 

R. Passalacqua, C. Buzio, S. Buti, R. Labianca, C. Porta, C. Boni, E. Rondini, R. Camisa, R. Sabbatini, F. Artioli, C. Caminiti.

Adjuvant low-dose interleukin-2 (IL-2) plus interferon-alpha (IFN-alpha) in operable renal cell cancer (RCC): a phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC).

Abs LBA5028, Proceedings of ASCO 43rd Annual Meeting, vol. 25, 2007

S. Buti, S. Lazzarelli, C. Simonelli, S. Venturini, S. Spazzapan, G. Lo Re, R. Mattioli, M. Dalla Chiesa, M. Brighenti, R. Passalacqua

Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial.

Abs 15586, Proceedings of ASCO 43rd Annual Meeting, vol. 25, 2007 

 

S. Bracarda, C. Porta, C. Boni, A. Santoro, F. Artioli, C. Di Bartolomeo, A. Contu, D. Gasparro, V. De Angelis, C Caserta.

Randomized prospective phase II trial of two schedules of sorafenib and interferon-a2a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC study 0681.

Abs 5100, Proceedings of ASCO 43rd Annual Meeting, vol. 25, 2007 


 

Boni C., Baldini E., Boni L., Tiseo M., Recchia F., Barone C., Manzione L., Zanelli F., Prochilo T., Ardizzoni A.

Triplets versus doublets with or without cisplatin in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: preliminary results of a multicenter randomized factorial study.

Abs A3-06, Journal of thoracic oncology, vol. 2, num. 8, supp. 4, 2007.


 

Bracarda S., Porta C., Boni C., Santoro A., Artioli F., Di Bartolomeo C., Contu A., Gasparro D., Di Costanzo F., Labianca R., Falcone A., De Angelis V., Caserta C., Sordini L.

RAPSODY: randomized prospective phase II trial of two schedules of sorafenib daily and interferon -a2A (IFN) in metastatic renal cell carcinoma (MRCC). GOIRC study 0681.

Abs 2*, Annals of Oncology 18 suppl. 11, 2007. 

 

Tiseo M., Boni C., Baldini E., Boni L., Recchia F., Barone C., Manzione L., Grossi F., Matano E., Zanelli F., Prochilo T., Ardizzoni A.

Triplets versus doublets with or without cisplatin in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: preliminary results of a multicenter randomized factorial study.

Abs B53*, Annals of Oncology 18 suppl. 11, 2007. 

 

Buti S., Lazzarelli S., Simonelli C., Venturini S., Spazzapan S., Lo Re Giovanni., Mattioli R., Dalla Chiesa M., Brighenti M., Mazza G., Passalacqua R.

Bevacizumab plus immunotherapy with interleukin-2 (IL-2) and interferon-a ( IFN-a) plus chemotherapy (BIC) in patients with metastatic renal cancer (mRCC). Dose-finding/phase II trial.

Abs D115*, Annals of Oncology 18 suppl. 11, 2007. 

 

Passalacqua R. Buzio C., Potenzoni D., Buti S., Labianca R.,  Porta C., Natasi P., Rondini E., Camisa R., Sabbatini R., Artioli F., Alberici F., Bongiovanni C., Pezzuolo D., Caminiti C.

Adjuvant low-dose  interleukin-2 (IL-2) plus interferon-alpha (IFN-alpha) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC).

Abs D118*, Annals of Oncology 18 suppl. 11, 2007.

R. Passalacqua, S. Buti, L. Rivoltini, C. Castelli, C. Camisaschi, C. Simonelli, G. Lo Re, R. Mattioli, G. Mazza, M. Brighenti, S. Lazzarelli

Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC).

Abs 5121 Proceedings of ASCO 44th Annual Meeting, vol. 26, 2008


S. Buti, S. Lazzarelli, C. Simonelli, A. Lleshi, L. Giovanni, R. Mattioli, M. Dalla Chiesa, R. Passalacqua

Dose-finding/phase II trial with a combination of bevacizumab (B) plus immunotherapy plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): A GOIRC multicentre study.

Abs 354 Proceedings of ASCO 44th Annual Meeting, vol. 26, 2008


G. Colucci, R. Labianca, F. Di Costanzo, V. Gebbia, G. Cartenì, B. Massidda, L. Frontini, M. Falconi, C. Gallo, M. Di Maio

A randomized trial of gemcitabine (G) vs G plus cisplatin in chemotherapy-naïve advanced pancreatic adenocarcinoma: the GIP-1 (Gruppo Italiano Pancreas-GOIM/GISCAD/GOIRC).

Abs 4504 Proceedings of ASCO 45th Annual Meeting, 2009


M. Dalla Chiesa, R. Poli, G. Tomasello, S. Lazzarelli, S. Buti, M. Brighenti, F. Negri, A. Curti, A. Auzzani, R. Passalacqua

Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study.

Abs 4142 Proceedings of ASCO 46th Annual Meeting, 2010


R. Passalacqua, S. Buti, M. Brighenti, L. Rivoltini, C. Castelli, C. Camisaschi, C. Simonelli, G. Lo Re, R. Mattioli, S. Lazzarelli;

Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG).

Abs 4615 Proceedings of ASCO 46th Annual Meeting, 2010


S. Bracarda, V. Ludovini, C. Porta, C. Boni, A. Santoro, D. Gasparro, E. Cortesi, V. De Angelis, M. Sisani, L. Crinò, GOIRC Group

Serum thrombospondin-1 (TSP-1), vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), and basic-fibroblast growth factor (b-FGF) as predictive factors for sorafenib plus interferon-alfa-2a (IFN) in metastatic renal cell carcinoma (MRCC): Biologic results from the randomized phase II RAPSODY trial.

Abs 4628 Proceedings of ASCO 46th Annual Meeting, 2010